Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The drug is administered subcutaneously ... investigating treatments for people living with hemophilia. In April, the FDA ...
Zacks.com on MSN15d
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to ...
Armed robbery in Revesby10d
FDA Greenlights Pfizer's HYMPAVZI for Hemophilia A/B
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine ...
technologynetworks1mon
New Hemophilia Treatment Approved by FDA
“Today’s approval of Hympavzi provides patients with hemophilia a new treatment ... The FDA granted Hympavzi Orphan Drug designation for this application. The FDA granted the approval of Hympavzi to ...
MarketWatch16d
Pfizer Gets European Approval of Hympavzi Hemophilia Drug
Pfizer has won European ... Union for people with severe hemophilia B and the first to be administered via a pre-filled pen or syringe for those with severe hemophilia A or B. The U.S. Food and Drug ...
FierceBiotech24d
Centessa drops phase 2 hemophilia B drug in wake of Pfizer’s Hympavzi approval
Centessa had recently conducted an interim analysis of a phase 2 study of its drug ... regulatory wins for Pfizer. First, the Big Pharma scored an FDA approval for its hemophilia B gene therapy ...
BioPharma Dive13d
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
On Friday, the FDA approved BridgeBio Pharma, Inc.’s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) ...
Drug offers cost-effective protection for newborns with genetic bleeding disorder
Severe hemophilia A is a genetic disorder that prevents blood from clotting properly, posing a constant risk of dangerous ...
Hemophilia B Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Pipeline, Epidemiology and Companies by DelveInsight
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...
Nasdaq15d
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Based on these results, the FDA approved this drug for a similar indication ... decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in July, the FDA ...